ReviewNature medicine2024
Integrating liver endpoints in clinical trials of cardiovascular and kidney disease.
Review in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Efficacy and Hypoglycaemia Outcomes With Once-Weekly IcoSema Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A Post Hoc Analysis of the COMBINE 1-3 Trials.Diabetes, obesity & metabolism · 2026Trial
- The case for cardiovascular-kidney-liver-metabolic syndrome.Nature reviews. Nephrology · 2026Article
- Gut‑liver‑kidney axis: A systems biology framework for understanding and treating chronic kidney disease (Review).International journal of molecular medicine · 2026Review
- Heart-liver co-management in MASLD: expert perspectives and recommendations from a multidisciplinary cardiometabolic framework.Nature reviews. Gastroenterology & hepatology · 2026Review
- The global cardiovascular-kidney-liver-metabolic burden from 1990 to 2023.EClinicalMedicine · 2026Article
- Metabolic disorder-MASLD-cardiovascular disease-kidney disease (MMCK) syndrome: an expansion of the Cardiovascular-Kidney-Metabolic (CKM) framework.Cardiovascular diabetology. Endocrinology reports · 2026Review
- Mechanistic insights and evidence-based management of metabolic dysfunction-associated steatotic liver disease (MASLD; formerly NAFLD) through combined diet and exercise interventions: an evidence-based narrative review.Journal of clinical biochemistry and nutrition · 2026Review
- Assessing Europe's policy readiness to confront the MASLD/MASH public health threat.The Lancet regional health. Europe · 2026Review
- MASLD as a systemic metabolic disease: expanding the scope of cardiovascular-kidney-metabolic (CKM) syndrome.Science China. Life sciences · 2026Review
- Inflammatory Adipokines and Potential Oxidative Stress-Related Mechanisms Linking MASLD with Subclinical Atherosclerosis Within CKM Syndrome: A Systematic Review and Meta-Analysis.Antioxidants (Basel, Switzerland) · 2026Review
- Liver fibrosis biomarkers as a prognostic tool beyond the defining components in cardiovascular-kidney-metabolic syndrome.American journal of preventive cardiology · 2026Article
- The global cardiovascular-liver-metabolic syndemic: epidemiology, trends and challenges.Nature reviews. Cardiology · 2026Review
- From Adipose Dysfunction to Multi-Organ Steatosis: Defining the Metabolic Steatotic Axis.Current issues in molecular biology · 2026Review
- The evolving concept from Cardiovascular-kidney-metabolic syndrome to metabolic associated liver-cardiovascular-kidney syndrome: insights from endocrinology.Reviews in endocrine & metabolic disorders · 2026Review
- Evaluation, Management and Therapeutic Approach of Cardiovascular-Kidney-Metabolic Syndrome: A Multidisciplinary Delphi Expert Consensus.Journal of clinical medicine · 2025Article
- Systemic Interactions in HFpEF: A Multiorgan Perspective on Pathways and Therapeutic Targets.Journal of cardiovascular translational research · 2025Review
- Met-ALD and ALD- Does Differentiating These Impact Management and Clinical Outcomes?Current hepatology reports · 2025Article
- Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease.Nature reviews. Gastroenterology & hepatology · 2025Review
- Inverse relationship between dietary index for gut microbiota and cardiovascular-kidney-metabolic syndrome among the general adult population.Scientific reports · 2025Article
- Liver native T1 mapping for predicting cardiovascular outcomes across stages of heart failure.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The intersection of cardiovascular disease, metabolic disorders and chronic kidney disease represents a complex clinical picture challenging healthcare systems worldwide. Metabolic-dysfunction-associated steatotic liver disease (MASLD) often manifests sequentially or concomitantly with these diseases, and may share underlying mechanisms and risk factors. Growing evidence suggests that new therapies could have benefits across these diseases, but trial sponsors and investigators tend to be reluctant to include patients with comorbidities-particularly liver diseases-in clinical trials. In this Perspective, we call for inclusion of patients with MASLD and measurement of liver outcomes in cardio-kidney-metabolic trials, when data suggest mechanistically plausible benefits and liver and cardiovascular safety. We discuss the implications of this new paradigm for clinical trial design and considerations for regulatory approval. Finally, we outline the challenges to implementing such an approach and provide recommendations for future clinical trial conduct.
Indexed as
Identifiers
39227442What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.